Generation of functional human ipsc-derived pancreatic islets in co-culture with isogenic ipsc-derived vascular endothelial cells
US-2024093154-A1 · Mar 21, 2024 · US
US9670519B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9670519-B2 |
| Application number | US-201214114525-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 27, 2012 |
| Priority date | Apr 29, 2011 |
| Publication date | Jun 6, 2017 |
| Grant date | Jun 6, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure relates to methods of decreasing lactate production in cell culture using divalent transitional metallic salts. The present disclosure also relates to a method of producing polypeptide by adding divalent transitional metallic salt to the cell culture medium for reducing lactate accumulation followed by fermenting and recovering the polypeptide.
Opening claim text (preview).
We claim: 1. A method for reducing accumulation of lactate from 5% to 40% in a cell culture of Chinese Hamster Ovary (CHO cells) comprising: a) growing said CHO cells in culture at 37±1° C. for 3-4 days in the presence of zinc salt at a concentration ranging from 0.2 mM to 0.4 mM; b) reducing the temperature in the culture resulting from a) to 31±1° C. and further culturing said cells for 3-4 days, so as to reduce accumulation of lactate by 5% to 40% in the cell culture at the end of the culture period relative to a control which is not supplemental with zinc salt. 2. The method as claimed in claim 1 , wherein the zinc salt is zinc sulphate. 3. The method of claim 2 , wherein the zinc sulphate is zinc sulphate hepta hydrate salt. 4. The method as claimed in claim 1 , wherein the culturing is carried out in a system selected from the group consisting of fed batch culturing, batch culturing, shake flasks and bioreactor.
against molecules with a "CD"-designation, not provided for elsewhere · CPC title
Metals; Metal chelators · CPC title
Culture media for cell or tissue culture (media for specific animal cell type C12N5/06) · CPC title
against receptors for growth factors, growth regulators · CPC title
against receptors for cytokines, lymphokines, interferons · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.